IPF Resources and Support

At Boehringer Ingelheim, we provide innovative treatments for Chronic Obstructive Pulmonary Disease (COPD), Idiopathic Pulmonary Fibrosis (IPF) and Asthma.

IPF is a condition of the lungs where tissue becomes thickened, stiff, and scarred over a period of time without a known cause. Research has identified key factors in the development of IPF, but no direct cause.

These key factors are:

  • Smoking
  • Viral infections
  • Certain medicines
  • Pollutants in the environment (from industry or work place)
  • Gastro-esophageal reflex disease (reflux of stomach contents into your gullet, which may be inhaled into lungs)
  • Hereditary

Men are more commonly diagnosed with IPF and generally later on in life. IPF affects approximately 13 to 20 per 100,000 people worldwide.

Disclaimer

We recognise that the Internet serves a global community. The pharmaceutical industry, however, is subject to country specific regulatory considerations, which affect the information we can provide on our products. In addition, the registration status of pharmaceutical products may not be the same in different regions of the world and the approved product labels may also differ according to country specific requirements.

Therefore, please check the registration details of this/these product(s) locally in order to get up-to-date information.